• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心血管疾病或癌症病史是否会影响 SARS-CoV-2 感染后的死亡率?

Does a history of cardiovascular disease or cancer affect mortality after SARS-CoV-2 infection?

出版信息

Tidsskr Nor Laegeforen. 2020 Dec 29;140(2). doi: 10.4045/tidsskr.20.0956. Print 2021 Feb 2.

DOI:10.4045/tidsskr.20.0956
PMID:33528146
Abstract

BACKGROUND

Cardiovascular disease and cancer have been described as possible risk factors for COVID-19 mortality. The purpose of this study was to investigate whether a history of cardiovascular disease or cancer affects the risk of dying after a COVID-19 diagnosis in Norway.

MATERIAL AND METHOD

Data were compiled from the Norwegian Surveillance System for Communicable Diseases, the Norwegian Cardiovascular Disease Registry and the Cancer Registry of Norway. Univariable and multivariable regression models were used to calculate both relative and absolute risk.

RESULTS

In the first half of 2020, 8 809 people tested positive for SARS-CoV-2 and 260 COVID-19-associated deaths were registered. Increasing age, male sex (relative risk (RR): 1.5; confidence interval (CI): 1.2-2.0), prior stroke (RR: 1.5; CI: 1.0-2.1) and cancer with distant metastasis at the time of diagnosis (RR: 3.0; CI: 1.1-8.2) were independent risk factors for death after a diagnosis of COVID-19. After adjusting for age and sex, myocardial infarction, atrial fibrillation, heart failure, hypertension, and non-metastatic cancer were no longer statistically significant risk factors for death.

INTERPRETATION

The leading risk factor for death among individuals who tested positive for SARS-CoV-2 was age. Male sex, and a previous diagnosis of stroke or cancer with distant metastasis were also associated with an increased risk of death after a COVID-19 diagnosis.

摘要

背景

心血管疾病和癌症已被描述为 COVID-19 死亡的可能危险因素。本研究旨在调查在挪威,心血管疾病或癌症史是否会影响 COVID-19 诊断后的死亡风险。

材料和方法

数据来自挪威传染病监测系统、挪威心血管疾病登记处和挪威癌症登记处。使用单变量和多变量回归模型计算相对风险和绝对风险。

结果

2020 年上半年,8809 人 SARS-CoV-2 检测呈阳性,登记了 260 例 COVID-19 相关死亡。年龄增长、男性(相对风险(RR):1.5;置信区间(CI):1.2-2.0)、既往卒中(RR:1.5;CI:1.0-2.1)和诊断时存在远处转移的癌症(RR:3.0;CI:1.1-8.2)是 COVID-19 诊断后死亡的独立危险因素。在调整年龄和性别后,心肌梗死、心房颤动、心力衰竭、高血压和非转移性癌症不再是死亡的统计学显著危险因素。

解释

在 SARS-CoV-2 检测呈阳性的个体中,死亡的主要危险因素是年龄。男性、既往卒中或诊断时存在远处转移的癌症也与 COVID-19 诊断后死亡风险增加相关。

相似文献

1
Does a history of cardiovascular disease or cancer affect mortality after SARS-CoV-2 infection?心血管疾病或癌症病史是否会影响 SARS-CoV-2 感染后的死亡率?
Tidsskr Nor Laegeforen. 2020 Dec 29;140(2). doi: 10.4045/tidsskr.20.0956. Print 2021 Feb 2.
2
Factors associated with hospitalization, invasive mechanical ventilation treatment and death among all confirmed COVID-19 cases in Norway: Prospective cohort study.与挪威所有确诊 COVID-19 病例住院、有创机械通气治疗和死亡相关的因素:前瞻性队列研究。
Scand J Public Health. 2021 Feb;49(1):41-47. doi: 10.1177/1403494820985172. Epub 2021 Jan 18.
3
Deaths after confirmed SARS-CoV-2 in Norway.挪威确诊感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)后的死亡情况。
Tidsskr Nor Laegeforen. 2020 Dec 3;140(18). doi: 10.4045/tidsskr.20.0693. Print 2020 Dec 15.
4
Multivariate mortality analyses in COVID-19: Comparing patients with cancer and patients without cancer in Louisiana.多变量 COVID-19 死亡率分析:比较路易斯安那州的癌症患者和非癌症患者。
Cancer. 2021 Jan 15;127(2):266-274. doi: 10.1002/cncr.33243. Epub 2020 Oct 28.
5
High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR.癌症患者出现 COVID-19 症状,无论 RT-PCR 是否检测到 SARS-COV-2,死亡率均较高。
Eur J Cancer. 2020 Aug;135:251-259. doi: 10.1016/j.ejca.2020.05.028. Epub 2020 Jun 7.
6
SARS-CoV-2 in children and adolescents in Norway: confirmed infection, hospitalisations and underlying conditions.挪威儿童和青少年中的新型冠状病毒肺炎:确诊感染、住院情况及潜在疾病
Tidsskr Nor Laegeforen. 2020 Jun 24;140(11). doi: 10.4045/tidsskr.20.0457. Print 2020 Aug 18.
7
[Impact of the COVID-19 epidemic in Friuli Venezia Giulia Region (Northern Italy): assessment of factors associated with the risk of death by competing risks analysis].[新冠疫情对弗留利-威尼斯朱利亚大区(意大利北部)的影响:通过竞争风险分析评估与死亡风险相关的因素]
Epidemiol Prev. 2020 Sep-Dec;44(5-6 Suppl 2):128-135. doi: 10.19191/EP20.5-6.S2.111.
8
[Association of cardiovascular disease with hospital mortality in COVID-19 patients].[新型冠状病毒肺炎患者心血管疾病与医院死亡率的关联]
Kardiologiia. 2023 Nov 8;63(10):63-71. doi: 10.18087/cardio.2023.10.n2408.
9
COVID-19 in Cancer Patients, Risk Factors for Disease and Adverse Outcome, a Population-Based Study From Norway.癌症患者中的COVID-19、疾病和不良结局的风险因素,一项基于挪威人群的研究
Front Oncol. 2021 Mar 25;11:652535. doi: 10.3389/fonc.2021.652535. eCollection 2021.
10
Identification of risk factors for in-hospital death of COVID - 19 pneumonia -- lessions from the early outbreak.鉴定 COVID-19 肺炎院内死亡的风险因素——来自早期爆发的教训。
BMC Infect Dis. 2021 Jan 25;21(1):113. doi: 10.1186/s12879-021-05814-4.

引用本文的文献

1
Risk factors for SARS-CoV-2 related mortality and hospitalization before vaccination: A meta-analysis.接种疫苗前与SARS-CoV-2相关的死亡和住院的危险因素:一项荟萃分析。
PLOS Glob Public Health. 2022 Nov 2;2(11):e0001187. doi: 10.1371/journal.pgph.0001187. eCollection 2022.
2
Methodological Considerations on COVID-19 Mortality in Cancer Patients: A Systematic Review and Meta-Analysis.关于癌症患者 COVID-19 死亡率的方法学考虑:系统评价和荟萃分析。
JNCI Cancer Spectr. 2022 Sep 1;6(5). doi: 10.1093/jncics/pkac063.
3
The effects of hypertension on the prognosis of coronavirus disease 2019: a systematic review and meta-analysis on the interactions with age and antihypertensive treatment.
高血压对 2019 年冠状病毒病预后的影响:一项关于与年龄和降压治疗相互作用的系统评价和荟萃分析。
J Hypertens. 2022 Dec 1;40(12):2323-2336. doi: 10.1097/HJH.0000000000003266. Epub 2022 Aug 8.
4
Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis.实体瘤或血液系统恶性肿瘤合并 SARS-CoV-2 感染的成年患者的死亡率:一项系统评价和荟萃分析,重点关注肺癌和乳腺癌。
Crit Rev Oncol Hematol. 2021 Jul;163:103365. doi: 10.1016/j.critrevonc.2021.103365. Epub 2021 May 27.